In recent years, inhibitors of the sodium-dependent glucose co-transporter 2 (SGLT2) have received marketing approval as antidiabetic agents following positive cardiovascular outcome trials: in the EMPA-REG Outcome trial, the SGLT2 inhibitor empagliflozin reduced the risk of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke by 14% compared with placebo, mainly due to a strong reduction in cardiovascular death [2]. Here, SLC5A2 is linked to myocardial infarction.